Litcius/Paper detail

Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials

Michał Marczyk, Anna Mrukwa, Christina Yau, Denise M. Wolf, Y.-Y. Chen, Ronald Balassanian, Rita Nanda, Barbara A. Parker, Gregor Krings, Husain Sattar, Jay Zeck, Kathy S. Albain, Judy C. Boughey, M.C. Liu, Anthony Elias, Amy S. Clark, Sara J. Venters, Sonal Shad, Amrita Basu, Smita Asare, Meredith Buxton, Adam L. Asare, Hope S. Rugo, Jane Perlmutter, Angela DeMichele, Douglas Yee, Donald A. Berry, Laura Van't Veer, W. Fraser Symmans, Laura J. Esserman, Lajos Pusztai

2022Annals of Oncology21 citationsDOIOpen Access PDF

Topics & Concepts

MedicineBreast cancerRandomized controlled trialOncologyCancerChemotherapyNeoadjuvant therapyInternal medicineMetric (unit)Operations managementEconomicsBreast Cancer Treatment StudiesGlobal Cancer Incidence and ScreeningCancer Risks and Factors
Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials | Litcius